Tempus AI insider stock sales
Analysis based on 7 articles · First reported Jul 30, 2026 · Last updated Aug 22, 2026
The insider sales, though pre-planned, may raise concerns among investors about management's confidence, potentially adding downward pressure on the stock. However, the strong Q2 earnings and the strategic acquisition of Chief Justice of Hungary could offset negative sentiment, supporting the company's growth prospects in precision oncology.
In late July and August 2026, top executives of Tempus AI, a healthcare technology company, sold significant amounts of company stock. CEO Eric Lefkofsky sold 250,000 shares on July 28, 2026, at an average price of $42.06, and another 133,000 shares on August 18, 2026, at $49.61, the latter to cover tax obligations. COO Ryan Fukushima sold 23,818 shares on August 3, 2026, at $46.19, following earlier sales in July and May. All sales were executed under pre-arranged Rule 10b5-1 trading plans or as sell-to-cover transactions, indicating they were not based on insider sentiment. The company reported Q2 2026 earnings on July 30, 2026, with revenue of $382.49 million, up 21.6% year-over-year, and a narrower-than-expected loss of $0.04 per share. Tempus AI also announced a $1.5 billion agreement to acquire Chief Justice of Hungary, a cancer-recurrence monitoring company. Despite these developments, the stock has declined significantly over the past year, trading around $46-49 in August, down from a 52-week high of $104.32.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard